Department of Surgery, The Ohio State University, Columbus, Ohio 43210, USA.
J Clin Endocrinol Metab. 2010 May;95(5):2187-94. doi: 10.1210/jc.2010-0063. Epub 2010 Mar 23.
The objective of the study was to determine the outcome of surgical resection of metastatic papillary thyroid cancer (PTC) in cervical lymph nodes after failure of initial surgery and I(131) therapy.
This was a retrospective clinical study.
The study was conducted at a university-based tertiary cancer hospital.
A cohort of 95 consecutive patients with recurrent/persistent PTC in the neck underwent initial reoperation during 1999-2005. All had previous thyroidectomy (+/-nodal dissection) and I(131) therapy. Twenty-five patients with antithyroglobulin (Tg) antibodies were subsequently excluded.
Biochemical complete remission (BCR) was stringently defined as undetectable TSH-stimulated serum Tg.
A total of 107 lymphadenectomies were undertaken in these 70 patients through January 2010. BCR was initially achieved in 12 patients (17%). Of the 58 patients with detectable postoperative Tg, 28 had a second reoperation and BCR was achieved in five (18%), seven had a third reoperation, and none achieved BCR. No patient achieving BCR had a subsequent recurrence after a mean follow-up of 60 months (range 4-116 months). In addition, two more patients achieved BCR during long-term follow-up without further intervention. In total, 19 patients (27%) achieved BCR and 32 patients (46%) achieved a TSH-stimulated Tg less than 2.0 ng/ml. Patients who did not achieve BCR had significant reduction in Tg after the first (P < 0.001) and second (P = 0.008) operations. No patient developed detectable distant metastases or died from PTC.
Surgical resection of persistent PTC in cervical lymph nodes achieves BCR, when most stringently defined, in 27% of patients, sometimes requiring several surgeries. No biochemical or clinical recurrences occurred during follow-up. In patients who do not achieve BCR, Tg levels were significantly reduced. The long-term durability and impact of this intervention will require further investigation.
本研究旨在探讨初始手术和碘-131 治疗失败后,手术切除颈部淋巴结转移性甲状腺乳头状癌(PTC)的结果。
这是一项回顾性临床研究。
该研究在一所大学附属的三级癌症医院进行。
1999 年至 2005 年期间,95 例颈部复发性/持续性 PTC 患者接受了初始再次手术。所有患者均接受过甲状腺切除术(+/-淋巴结清扫术)和碘-131 治疗。随后排除了 25 例抗甲状腺球蛋白(Tg)抗体阳性的患者。
严格定义生化完全缓解(BCR)为促甲状腺激素刺激的血清 Tg 不可检测。
截至 2010 年 1 月,对这 70 例患者共进行了 107 次淋巴结切除术。12 例患者(17%)首次达到 BCR。在 58 例术后 Tg 可检测的患者中,28 例接受了二次手术,其中 5 例(18%)达到 BCR,7 例接受了三次手术,均未达到 BCR。无 BCR 患者在平均 60 个月(4-116 个月)的随访中无复发。此外,另有 2 例患者在长期随访中无需进一步干预即达到 BCR。总的来说,19 例患者(27%)达到 BCR,32 例患者(46%)达到 TSH 刺激的 Tg<2.0ng/ml。未达到 BCR 的患者在第一次(P<0.001)和第二次手术(P=0.008)后 Tg 明显下降。无患者发生可检测的远处转移或死于 PTC。
当最严格地定义时,手术切除颈部淋巴结持续性 PTC 可使 27%的患者达到 BCR,有时需要进行多次手术。在随访期间无生化或临床复发。在未达到 BCR 的患者中,Tg 水平显著降低。这种干预的长期耐久性和影响需要进一步研究。